Eli Lilly and Company
NYSE:LLYDrug Manufacturers - General
-$10.54 today
- Market cap
- $1.30T
- Beta
- 0.52
- P/E (TTM)
- 39.0
- EPS (TTM)
- $28.26
- Dividend yield
- 0.59%
Volume 2.58M
Average 3.19M
LLY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Eli Lilly and CompanyNYSE: LLY
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $3.82B rose 14.5% year over year, behind the +23.4% change in trailing-twelve-month research & development. Sequentially, it rose 8.8% from the prior quarter. Over 3 fiscal years it compounded at +22.9% a year.
Context
- Research & development amounted to 20.5% of revenue in FY2025, down 3.9 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +14.5% toward the trailing-twelve-month pace of +23.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 13.34B USD
- Year-over-year change
- +21.3%
- 4-year CAGR
- +17.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.34B | +21.3% |
| FY2024 | 2024-12-31 | 10.99B | +18.0% |
| FY2023 | 2023-12-31 | 9.31B | +29.5% |
| FY2022 | 2022-12-31 | 7.19B | +3.8% |
| FY2021 | 2021-12-31 | 6.93B | — |
Research & Development vs competitors
How LLY compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.4% is the 3rd highest of 10, against a peer median of +7.0%.
- Research & development amounts to 18.3% of revenue for LLY, versus a peer median of 17.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 58.11B DKK | +28.3% | +29.3% | 17.6% | |
| LTM Jun 2026 | $28.35B USD | +65.7% | -2.6% | 42.7% | |
| LTM Sep 2026 | $16.08B USD | +2.4% | +1.2% | 16.2% | |
| LTM Sep 2026 | $15.01B USD | -0.3% | +13.4% | 24.1% | |
| LTM Jun 2026 | $14.6B USD | +23.4% | +22.9% | 18.3% | |
| LTM Jun 2026 | $11.28B USD | +9.2% | +5.4% | 20.3% | |
| LTM Jun 2026 | $11.05B USD | +7.0% | -3.0% | 17.3% | |
| LTM Sep 2026 | $9.96B USD | -25.0% | +11.8% | 15.1% | |
| LTM Jun 2026 | €8.11B EUR | +5.4% | +6.5% | 16.6% | |
| LTM Jun 2026 | $7.64B USD | +19.3% | +16.3% | 20.0% | |
| Peer median (excluding LLY) | — | +7.0% | +6.5% | 17.6% | |
Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B |
| Cost of Revenue | 7.31B | 6.63B | 7.08B | 8.42B | 11.05B |
| Gross Profit | 21.01B | 21.91B | 27.04B | 36.63B | 54.13B |
| Gross Margin | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% |
| Research & Development | 6.93B | 7.19B | 9.31B | 10.99B | 13.34B |
| Selling, General & Admin | 6.14B | 6.07B | 6.94B | 8.59B | 11.09B |
| Operating Expenses | 13.07B | 13.26B | 16.25B | 19.59B | 24.43B |
| Depreciation & Amortization | 1.55B | 1.52B | 1.53B | 1.77B | 2B |
| EBITDA | 8.04B | 8.66B | 8.57B | 18.81B | 31.69B |
| EBITDA Margin | 28.4% | 30.3% | 25.1% | 41.8% | 48.6% |
| Operating Income | 7.93B | 8.65B | 10.79B | 17.04B | 29.7B |
| Operating Margin | 28.0% | 30.3% | 31.6% | 37.8% | 45.6% |
| Interest Income | 25.4M | 62.8M | 173.6M | 175.2M | 153.3M |
| Interest Expense | 339.8M | 331.6M | 485.9M | 780.6M | 795.3M |
| Other Income / Expenses | (1.78B) | (1.85B) | (4.23B) | (4.36B) | (3.97B) |
| Income Before Tax | 6.16B | 6.81B | 6.55B | 12.68B | 25.73B |
| Pre-Tax Margin | 21.7% | 23.8% | 19.2% | 28.2% | 39.5% |
| Income Tax Expense | 573.8M | 561.6M | 1.31B | 2.09B | 5.09B |
| Net Income | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B |
| Net Margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| EPS (Basic) | 5.85 | 6.57 | 5.83 | 11.76 | 23.07 |
| EPS (Diluted) | 5.85 | 6.57 | 5.80 | 11.71 | 22.95 |
| Weighted Avg Shares | 953.65M | 950.18M | 899.38M | 900.61M | 898M |
| Weighted Avg Shares (Diluted) | 953.65M | 950.18M | 903.28M | 904.06M | 898M |
Eli Lilly and Company
NYSE:LLY
Intrinsic Alpha fair value
Locked
Current Price
$1,382.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.